Research on isotretinoin and mental health asks two different questions: whether treated populations show more psychiatric problems overall, and what to do when an individual develops a new symptom. A reassuring answer to the first does not remove the need to act on the second.
Acne can already affect mood, confidence and relationships before a prescription begins. A useful treatment plan records that starting point and keeps the conversation open throughout the course.
What the larger studies show
A meta-analysis published in JAMA Dermatology in 2024 included 25 studies and 1,625,891 participants. It found no overall association between isotretinoin use and an increased relative risk of psychiatric disorders at the population level. The authors still advised monitoring for mental distress during treatment. 1
That result does not prove that no person can experience a medicine-related psychiatric reaction. The included studies used different populations and methods, and observational research can miss individual susceptibility or the reasons a clinician selected one treatment over another.
The study also does not justify describing every mood symptom as a proven isotretinoin effect. Timing, acne severity, other medicines, life events and pre-existing conditions can all matter. An assessment needs room for more than one possible contributor.
Why acne complicates the comparison
Severe acne can cause pain, embarrassment, social withdrawal and distress. A patient who begins isotretinoin may already face a different mental health burden from someone with mild acne or no acne. Comparing those groups without accounting for the starting differences can distort the apparent treatment effect.
Improved skin may support confidence and quality of life for some people. Others continue to struggle with scars, body image or unrelated depression even after active acne clears. Visible improvement does not guarantee that psychological distress ends on the same schedule.
These complications explain why the clinician should ask about wellbeing directly rather than infer it from the number of lesions. A smiling patient with clear skin can still need help.
The conversation before treatment
Tell the prescriber about current or past depression, anxiety, bipolar disorder, psychosis, self-harm and mental health treatment. Include medicines, therapy and the people or services you rely on for support. This history helps plan care; it should not become a reason to hide symptoms because you fear losing access to acne treatment. 2, 3
A previous diagnosis does not automatically decide whether isotretinoin suits you. The clinician may coordinate with another treating professional, establish a baseline assessment or arrange additional monitoring. The decision should consider current stability, risk, support and acne severity.
Ask how to contact the clinic between visits. Knowing who will respond and what to do outside office hours makes the plan more useful than a general instruction to report problems someday.
Changes worth reporting
Report a persistent change in mood, anxiety, sleep, behavior or functioning. A single difficult day does not diagnose a psychiatric disorder, but a worsening pattern deserves attention before it becomes a crisis.
- Low mood, hopelessness or loss of interest in usual activities.
- New or worsening anxiety that interferes with daily life.
- Marked irritability, agitation or a change others notice.
- A major change in sleep, energy or behavior.
- Unusual thoughts, hallucinations or loss of contact with reality.
- Thoughts of self-harm or suicide, or a feeling that you cannot stay safe.
Describe when the change began relative to starting treatment or changing the dose. The clinician also needs to know about other medicines, alcohol or recreational drug use and recent events. You do not need to establish the cause before asking for help.
When to stop and seek urgent help
US labeling instructs patients to stop isotretinoin and contact the prescriber promptly if depression, psychosis, suicidal thoughts or concerning behavioral symptoms develop. Stopping alone may not resolve the problem, so an assessment remains necessary. 2, 3
If you have an immediate risk of harming yourself, severe confusion, psychotic symptoms or an inability to stay safe, seek emergency medical help. Do not wait for a routine acne appointment or attempt to settle the cause through an online discussion.
For less acute changes, contact the clinic promptly and follow the agreed instructions. Do not quietly reduce the dose and assume that this replaces a mental health evaluation.
Monitoring during the course
Follow-up should give you a chance to describe how you feel, not only show the skin. Some clinics use questionnaires to track symptoms. Those tools support the conversation; they do not overrule a concerning change that you or someone close to you notices.
| Stage | Useful information | What it supports |
|---|---|---|
| Before starting | Current symptoms, history, treatment and support | A baseline and an individual follow-up plan |
| During treatment | New symptoms, dose changes and daily functioning | Earlier identification of a worsening pattern |
| After a concern arises | Severity, safety, other contributors and timing | A decision about stopping, further assessment and support |
| After the course | Whether symptoms have resolved or continue | Ongoing care that does not end with the acne prescription |
If you want to involve a trusted person, discuss what you would like them to notice and how to raise a concern. They can support observation without becoming responsible for diagnosing a reaction or policing your treatment.
Sexual function belongs in follow-up too
Some patients report changes in libido or other aspects of sexual function during or after isotretinoin. UK regulatory guidance requires assessment and monitoring of mental health and sexual function, while acknowledging limits in the evidence about causation. Report a new problem rather than assume that acne treatment could not relate to it. 4, 6
The assessment should also consider mood, other medicines, relationships and physical health. A symptom can deserve care even when the precise contribution of isotretinoin remains uncertain.
Do not add an erectile dysfunction medicine or hormone product simply to counter a new symptom without medical review. The clinician first needs to understand the pattern and determine which treatment, if any, fits it.
Privacy and practical support
Tell the clinic if you need to discuss sensitive concerns privately. Younger patients may need a conversation that respects both appropriate family involvement and the ability to describe symptoms openly. Fear of embarrassment should not prevent reporting a change in mood or sexual function.
Support can continue alongside dermatology care. Therapy, treatment of an existing psychiatric condition and adjustments to the acne plan may each have a role. There is no requirement to choose between taking the skin problem seriously and taking mental health seriously.
Does the research prove isotretinoin is risk-free for mental health?
No. Population findings help assess average associations, but they cannot guarantee an individual outcome. The labeling and monitoring requirements remain relevant.
If I feel better as my acne improves, can I skip mood questions?
Continue the planned reviews. Improvement is useful information, and documenting it helps the clinician interpret any later change. Follow-up also covers risks that clear skin cannot reveal.
Can symptoms continue after stopping?
They can require ongoing assessment regardless of their cause. Contact the treating professionals if symptoms persist rather than assume that ending the prescription must resolve every problem immediately.
Sources
- Tan NKW, et al. Risk of suicide and psychiatric disorders among isotretinoin users: a meta-analysis. JAMA Dermatology, 2024. View source
- DailyMed. Isotretinoin capsules prescribing information, revised August 2026. View source
- FDA. Absorica and Absorica LD prescribing information, revised June 2026. View source
- NICE. Acne vulgaris: management, NG198. Recommendations, updated 2026. View source
- NHS. Isotretinoin: uses, precautions, interactions and side effects. View source
- MHRA. Isotretinoin: changes to prescribing guidance and risk minimisation measures, 2026. View source